Cytochrome P450 and Parkinsonism: Protective role of CYP2E1

Functional Neurology

Volumn 16, Issue 4 SUPPL., 2001, Pages 107-112

  Vaglini, Francesca ^a   Pardini, Carla ^a   Viaggi, Cristina ^a   Corsini, Giovanni U ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

CYP2E1; Cytochrome P450; MPP+; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 INHIBITOR; DEBRISOQUINE; DIETHYLDITHIOCARBAMIC ACID; QUINIDINE;

ANIMAL CELL; BRAIN METABOLISM; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG METABOLISM; DRUG POTENTIATION; EXPERIMENTAL MODEL; FUNCTIONAL ASSESSMENT; MOUSE; NERVOUS SYSTEM FUNCTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; TOXICITY TESTING; TREATMENT PLANNING; ANIMAL; CHEMICALLY INDUCED DISORDER; HUMAN; INTOXICATION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; HUMANS; MPTP POISONING; PARKINSONIAN DISORDERS;

EID: 0035544925     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Ecogenetics of Parkinson's disease: 4-Hydroxylation of debrisoquine
2. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
3. Expression and localization of CYP2D enzymes in rat basal ganglia
4. P450 enzymes and Parkinson's disease
5. P450 enzymes and Parkinson's disease: The story so far
6. Colocalization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase
7. Cytochrome P450 enzymes in brain
8. Dopamine quinone formation and protein modification associated with striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine
9. Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: Impact of ascorbic acid and glutathione
10. The pharmacology of 6-hydroxydopamine
11. + within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study
12. Neurotoxic phenylalkylamines and indolealkylamines
13. Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: A possible causative protoxin in idiopathic Parkinson's disease
14. Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neurons in spinal cord slices from adult rat
15. Mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced destruction of dopaminergic neurons
16. Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylenebis-dithiocarbamate)
17. SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment
18. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part I
19. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate
20. MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra
21. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in primates
22. The effect of diethyldithiocarbamate on the biodisposition of MPTP: An explanation for enhanced neurotoxicity
23. In Brown Norway rats, MPP+ is accumulated in nigrostriatal dopaminergic terminals but it is not neurotoxic: A model of neural resistance to MPTP toxicity
24. (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice
25. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
26. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation
27. Metabolism of the neurotoxic tertiary amine MPTP, by brain monoamine oxidase
28. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP
29. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
30. 3H]1-methyl-4-phenyl-2,3,-dihydropyridinium ion to mouse striatal membranes: Putative vesicular location
31. Interaction of 1-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine
32. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitro
33. Energy-dependent uptake of 1-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria
34. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rat, guinea pig and monkey
35. +) within catecholaminergic neurons
36. + levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice
37. Molecular and cellular events regulating dopamine neuron survival
38. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects
39. Biotransformation of xenobiotics